Pandemic Lipid Edition

Slides:



Advertisements
Similar presentations
Clinical question: When do you get statin induced myopathy?
Advertisements

Anti-Hypercholesterolemic Agents  Biosynthesis and Metabolism of Cholesterol  What is arteriosclerosis? - Link between arteriosclerosis and cholesterol.
DYSLIPIDEMIA IN ADULTS WITH DIABETES* 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada *Updated in Leiter.
DYSLIPIDEMIA STEP 5. Simvastatin: Effects of the Drug An HMG-CoA reductase inhibitor (statin) Used together with lifestyle changes (smoking cessation,
New Agents Heather Kertland, PharmD.
STATINS AGAIN. Atorvastatin Off patent Atorvastatin 40 = £36 PA Simvastatin 40 = £14 PA Atorvastatin 80 = £72 PA Simvastatin 80 = £24 PA.
Praluent® - alirocumab
Team Based Care Combining Team Based Care and Technology to Improve Quality and Transform Healthcare to Improve Blood Pressure Control Wednesday February.
Case 15 Andrea De Mesa. Patient history A 44 y/o male, single, undergoes cardiovascular screening on advice of his attending physician. He is a smoker.
Statin Induce Myotoxicity
HLD Tx & AHA/ACC Guidelines
Manufacturer: Amgen Inc FDA Approval Date: August 27, 2015
ACC/AHA Guidelines Not the Final or Only Word. Contemporary Guidelines
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults Scott W. Rypkema, M.D.
Efficiently dealing with new FDA information on drug safety Warnings, Shortages, Withdrawals – Oh My! Efficiently dealing with new FDA information on drug.
Therapeutics 1 Tutoring
North Bay Educational Symposium CANP North Bay Chapter January 30, 2016 Gregg Hopkins, MD, FACC Sutter Medical Group of the Redwoods.
Neal S. Perlmutter, MD, FACC Overlake Medical Clinics Cardiology
Hyperlipidemia: Management of Patients in the Primary Care Setting
18th Annual Primary Care & Cardiovascular Symposium
Repatha ( Evolocumab) Praluent (Arilocumab)
Statins induced myopathy
Evolocumab Drugbank ID : DB09303.
Anti-Hypercholesterolemic Agents
Dyslipidemia and Primary Prevention
Familial Hypercholesterolaemia
Intensive Statin Recommendations
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation.
The Latest Lipid Guidelines:
Updates and Perspectives in Diabetic Dyslipidemia
Antilipidaemic agents
LDL Established Target for Cardiovascular Risk
Comprehensive Diabetes Care
An Endocrinology Clinic in Dyslipidemia
Drug induced myopathy Edition
A multicenter, double-blind, randomized study to establish the clinical benefit and safety of ezetimibe/simvastatin tablet (vytorin) vs simvastatin.
Cardiovascular Disease Risk Reduction Advances in Dyslipidemia
Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?
Patients aged 85yrs and over
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial.
Management of Post-transplant hyperlipidemia
Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY.
Lipid Treatment Updates in Management
Diabetes Dr. J. Antony Gagnon, Pharm.D., CDE, CAE
LDL-C Goals. The Patient With Difficult-to-Treat Hypercholesterolemia: Is Everything Under Control?
Statin Class in Session
An Update on PCSK9 Inhibitors
Evaluating LDL-C Recommendations
Statin Class in Session
PCP View: ACC/AHA Guidelines: Role of Moderate Intensity Statins
My Approach to the Patient With Familial Hypercholesterolemia
% decrease in LDL-C at 24 weeks from baseline
Clinicians' Corner in Dyslipidemia
By Nancy Dagefoerde MSN, FNP-BC
Dallas Heart Study Lipid Characteristics of Blacks With Nonsense Mutations in PCSK9
Advances in Hypertriglyceridemia Treatment
Rational Order of Laboratory Tests in Cardiovascular Diseases
An Update on PCSK9 Inhibitors
Major classes of drugs to reduce lipids
Train-the-Trainer Cases
Updates on Dyslipidemia
Preventative Cardiology
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
Train-the-Trainer Cases
Train-the-Trainer Cases
Lipids, the Heart, and the Kidney
Case—History 75 year old woman referred for statin intolerance in 2016
ATP III Guidelines Drug Therapy FUTURE RESEARCH.
Section 6: Update on lipid treatment guidelines
Presentation transcript:

Pandemic Lipid Edition A team-based mission to prevent Cardiovascular outcomes Pandemic

What is the specific statin agent and dose that is still on the market, but not recommended for initiation? Simvastatin 80 mg Due to the increased risk of myopathy, including rhabdomyolysis, use of the 80-mg dose of ZOCOR should be restricted to patients who have been taking simvastatin 80 mg chronically (e.g., for 12 months or more) without evidence of muscle toxicity. (2.2)

List at least two simvastatin drug-drug interactions - including max dose limitations Interacting Agents Simvastatin Recommendations Strong CYP3A4 inhibitors Contraindicated Verapamil, diltiazem, dronedarone 10 mg/day max Amlodipine, amiodarone, ranolazine 20 mg/day max Strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, boceprevir, telaprevir, nefazodone, cobicistat- containing products), gemfibrozil, cyclosporine, danazol

Which statins include grapefruit juice precaution? L A S: Lovastatin, atorvastatin, simvastatin 8 oz of juice or 1 half a grapefruit unlikely to cause an issue – 3A4

List the statins and strengths considered high-intensity Atorvastatin 40 mg, 80 mg Rosuvastatin 20 mg, 40 mg At what age is moderate considered adequate for high risk patients? (age 75)

Meijer Pharmacy offers what statin for free? Atorvastatin 10-80 mg

Which two statins are the least lipophilic ? (hint: most hydrophilic) Pravastatin and rosuvastatin

Which statin is specifically market as being less likely to cause DDI? Pitavastatin (livalo) https://www.livalorx.com

Which omega-3 supplement is marketed to not increase LDL? Vacepa >96% EPA (not associated with  LDL)

Which medication used for TG lowering should be avoid with statins? Gemfibrozil

Which lipid medication is commonly associated with flushing? Niacin

What new class of lipid-lowering medications was recently FDA approved? PCSK9 Inhibitors Praluent (alirocumab) Repatha (evolocumab) PRALUENT (alirocumab) is a PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) inhibitor antibody indicated as adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, who require additional lowering of LDL-C. The effect of PRALUENT on cardiovascular morbidity and mortality has not been determined.

The Improve-it provided outcomes data with what medication? Vytorin (ezetimibe and simvastatin)

Heart Center of Excellence (bonus points) Name one of the statin + non lipid- lowering medication combos Caduet (amlodipine/atorvastatin) Liptruzet (Ezetimibe/atorvastatin) Juvisync (Sitagliptin/simvastatin)

The race to prevent CV death! Prevention  150 mins of physical activity/week >300 mins of PA/week 2 servings of fish per week Statin 5-10% weight loss BP <140/90

The race to prevent CVD outcomes! Risks  DM Smoker >2400mg of sodium/day BMI >25 Sedentary lifestyle HDL <50 HTN